Actaea Cimicifuga Whole Calcium Hexafluorosilicate
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
- Actaea Cimicifuga Whole Calcium Hexafluorosilicate
- ACTAEA CIMICIFUGA / DROSERA / INULA COMBINATION: INSUFFICIENT DATA TO COMPLETE DRUG REPURPOSING ASSESSMENT
ACTAEA CIMICIFUGA / DROSERA / INULA COMBINATION: INSUFFICIENT DATA TO COMPLETE DRUG REPURPOSING ASSESSMENT
One-Sentence Summary
This product is a combination formulation containing 8 components (including Actaea cimicifuga, Drosera rotundifolia, Inula helenium and other herbal and mineral components), currently Not marketed in both Taiwan and the United States. Since DrugBank cannot identify the complete combination formulation and there are no original indication records, the TxGNN model failed to generate any new indication predictions, and this assessment has insufficient data for complete analysis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No registration data |
| Predicted New Indication | No prediction results |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model failed to generate predictions, no evidence) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why Was Prediction Unable to Be Completed?
This combination contains 8 heterogeneous components (whole herb plants, mineral salts, insect extracts, fungi) and is in nature similar to homeopathic or anthroposophic formulations:
- Actaea cimicifuga (black cohosh), Drosera rotundifolia (sundew), Inula helenium (elecampane) are whole herb plants
- Formica rufa (red ant), Fuligo septica (dog vomit slime mold) are atypical biological sources
- Calcium hexafluorosilicate, Potassium chloride, Silica are mineral or inorganic components
The TxGNN knowledge graph uses single chemical entities recorded in DrugBank as core nodes and cannot handle combination formulations or homeopathic preparations. Therefore, this combination has no DrugBank ID and cannot be mapped to disease nodes, resulting in interruption of the prediction workflow.
US Market Information
Currently no US NDA or marketing records.
Safety Considerations
Please refer to the safety information in each component’s original prescribing information or pharmacopeias (such as the Homeopathic Pharmacopoeia of the United States, HPUS).
Conclusion and Next Steps
Decision: Hold
Rationale: This combination cannot generate predictions under the current TxGNN framework and has no marketing records in both Taiwan and the United States, lacking regulatory and clinical foundation for evaluation.
If further advancement is needed, the following data must be supplemented:
- Clarify formulation properties: Confirm whether it is a homeopathic/anthroposophic preparation or a herbal combination with clear pharmacological mechanisms
- Single-component analysis: If the target is specific components (such as Actaea cimicifuga for menopausal symptoms, Drosera rotundifolia for cough), each component should be independently submitted to the TxGNN workflow
- Literature basis confirmation: Search PubMed for clinical studies on this specific combination formulation
- Regulatory strategy assessment: Confirm the classification standards (drug vs. dietary supplement vs. homeopathic preparation) for such formulations in the target market (Taiwan/United States)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.